🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

IGC Pharma, Inc. IGC PHARMA

Healthcare · Biotechnology · United States
https://igcpharma.com
Company Profile ↓
$0.29
-19.47% 1Y
Mkt Cap$29.98M
P/E-4.83
P/B4.75
52W High$0.47
52W Low$0.24
Book Value$0.06
EPS (TTM)$-0.06

Company Overview

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.18.

Recent Developments

  • Mar 2025 Revenue of $1.27M (-5.5% YoY); net profit $-7.12M.
  • Trailing 12 Months Year-on-year growth — revenue -19.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR -8.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-7.98%
1 Year:-19.20%

Stock Price Performance

1 Year:-19.47%
6 Months:-0.03%
3 Months:-3.37%
1 Month:+11.50%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 22% of range
$0.24 $0.47
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)49.62 · Neutral
Price Performance
1M+11.50%
3M-3.37%
6M-0.03%
1Y-19.47%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -8.0% CAGR over 5 years.
  • Trading 38.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.83
Industry PE
24.83
Forward P/E
-3.62
PEG Ratio
-
Book Value
$0.06
Price to Book
4.75
P/S
26.64
EV/EBITDA
-3.76
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-7.98%
Profit 5Y
-
Revenue (YoY)
-19.20%
Earnings (YoY)
-

Profitability & Returns

ROCE
-114.73%
ROE
-83.34%
ROA
-50.31%
Profit Margin
0.00%
Op Margin
-
Gross Margin
46.20%
EPS (Latest Qtr)
$-0.02
EPS (TTM)
$-0.06

Balance Sheet & Liquidity

Debt/Equity
0.18
Quick Ratio
0.79
Current Ratio
1.32
Debt
$1.08M
Total Assets
$9.19M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
13.51%
Chg in Prom Hold
0.13%
FII / Inst Holding
22.09%
Chg in FII Hold
0.37%

Financial Snapshot

Enterprise Value
$29.98M
Total Revenue (TTM)
$1.11M
EBITDA
$-7.52M
Free Cash Flow
$-2.52M
Operating Cash Flow
$-5.54M
Shares Outstanding
103.38M
Gross Margin
46.20%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IGC IGC Pharma, Inc. PHARMA 0.29 -4.83 $29.98M 0.00% -114.73% -83.34% -7.98% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Dec 2013Jun 2014Sep 2014Dec 2014Jun 2015Sep 2015Dec 2015Jun 2016Sep 2016Dec 2016Jun 2017Sep 2017Dec 2017Jun 2018Sep 2018Dec 2018Jun 2019Sep 2019Dec 2019Jun 2020Sep 2020Dec 2020Jun 2021Sep 2021Dec 2021Jun 2022Sep 2022Dec 2022Jun 2023Sep 2023Dec 2023Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1.13M17.53K763.86K2.12M2.54M1.86M2.06M1.08M288.49K162.16K249.80K52.93K235.00K762.00K1.48M811.00K1.28M1.65M1.82M573.00K584.00K125.00K108.00K77.00K56.00K142.00K212.00K202.00K332.00K555.00K291.00K204.00K272.00K412.00K-330.00K328.00K191.00K350.00K317.00K
Cost of Revenue -----------------------------------176.00K174.00K92.00K306.00K262.00K
Gross Profit -------------39.00K42.00K18.00K45.00K41.00K28.00K30.00K46.00K26.00K14.00K26.00K38.00K62.00K142.00K135.00K102.00K255.00K174.00K133.00K163.00K198.00K-154.00K154.00K99.00K44.00K55.00K
Operating Expenses -----------------------------------1.57M2.06M3.00M2.98M2.51M
Operating Income -432.71K-294.02K-1.15M-765.28K-499.15K-257.34K-508.22K-375.00K-318.81K-549.63K-386.11K-396.27K-263.00K-473.00K-511.00K-855.00K-1.58M-1.46M-1.29M-1.68M-1.93M-1.68M-2.33M-2.19M-4.35M-2.38M-2.80M-2.49M-2.28M-2.14M-2.49M-3.00M-2.40M-1.76M--1.41M-1.91M-2.90M-2.94M-2.46M
EBITDA ------------------------------------1.26M-1.76M-2.78M-2.88M-2.40M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------1.20M-1.60M-1.82M-726.00K-2.40M
Tax Provision -----------------------------------00000
Net Income -615.19K-310.48K-1.20M-887.40K-590.11K-382.70K-623.37K-403.00K-383.57K-583.87K-111.56K-432.14K-304.00K-532.58K-512.00K-859.00K-1.15M-1.38M-1.18M-1.60M-1.88M-1.66M-2.32M-1.79M-4.34M-2.38M-2.79M-2.44M-2.25M-2.08M-2.45M-5.59M-2.38M-1.72M--1.20M-1.60M-1.82M-726.00K-2.40M
Diluted EPS -0.09-0.04-0.12-0.07-0.05-0.03-0.04-0.02-0.02-0.020.00-0.02-0.01-0.02-----------------0.05-0.09-0.03-0.02-0.02--0.02-0.02--0.02
R&D Expense -----------56.54K78.00K036.00K278.00K166.00K247.00K222.00K295.00K222.00K219.00K154.00K444.00K276.00K377.00K1.39M768.00K806.00K747.00K1.27M903.00K889.00K917.00K852.00K997.00K851.00K1.59M-1.27M

Profit & Loss (Annual)

Figures in USD.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue 4.07M4.20M8.03M2.27M7.68M6.37M580.37K2.19M5.12M4.07M898.00K397.00K911.00K1.34M1.27M
Gross Profit ------218.24K82.00K132.00K115.00K113.00K194.00K442.00K733.00K619.00K
Operating Income -15.89M-7.51M-2.48M-2.53M-4.34M-2.91M-2.05M-1.79M-4.64M-6.86M-8.72M-15.43M-11.57M-9.80M-7.45M
Net Income -20.24M-7.75M-2.25M-3.02M-4.61M-2.81M-1.87M-1.79M-4.10M-7.32M-8.81M-15.02M-11.51M-13.00M-7.12M
Diluted EPS -1.34-2.66-0.32-0.37-0.31-0.17-0.07-------0.22-0.09
R&D Expense -------137.00K1.26M1.01M929.00K2.33M3.46M3.77M3.65M

Balance Sheet (Annual)

Figures in USD.

Metric Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets -18.16M25.26M19.25M17.73M20.33M18.86M11.28M10.85M34.47M28.98M35.87M26.83M17.18M9.90M8.75M
Total Equity 26.15M6.67M14.84M14.44M13.63M14.23M13.48M7.36M8.06M33.57M26.54M32.80M23.89M14.91M7.32M6.33M
Cash & Equivalents 842.92K1.58M562.95K1.06M1.03M824.49K1.49M538.00K1.66M25.61M7.26M14.55M10.46M3.20M1.20M405.00K
Long Term Debt ----0323.90K801.47K452.08K--0276.00K144.00K141.00K137.00K134.00K
Total Liabilities -7.79M9.44M4.28M3.59M5.58M4.91M3.93M2.79M893.00K2.45M3.06M2.94M2.27M2.58M2.42M
Current Liabilities -6.58M4.50M1.82M1.03M2.45M3.20M1.29M2.35M878.00K1.95M2.37M2.44M1.90M2.34M2.26M

Cash Flows (Annual)

Figures in USD.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow -2.63M-5.02M564.85K-1.74M-2.58M-157.70K-1.39M-1.93M-3.33M-8.68M-10.80M-7.46M-7.05M-5.20M-4.79M
Investing Cash Flow -44.70K4.67M-74.70K3.08K-518.09K-183.42K-241.35K-657.00K-260.00K-9.55M3.39M-742.00K-235.00K-317.00K-442.00K
Financing Cash Flow 3.41M-625.76K27.69K1.74M2.90M1.01M707.56K3.71M27.60M-59.00K14.69M4.14M100.00K3.52M4.45M
Capital Expenditure -285.44K-5.48K-326.08K-8.48K-76.53K-122.19K-145.68K-136.00K-15.00K-4.39M-1.47M-236.00K-310.00K-138.00K-112.00K
Free Cash Flow -2.92M-5.03M238.77K-1.75M-2.66M-279.89K-1.54M-2.07M-3.35M-13.07M-12.27M-7.70M-7.36M-5.34M-4.91M

Ratios (Annual)

Figures in %.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Gross Margin % ------37.6%3.7%2.6%2.8%12.6%48.9%48.5%54.5%48.7%
Operating Margin % -390.0%-178.9%-30.9%-111.2%-56.5%-45.6%-354.0%-81.6%-90.8%-168.6%-971.5%-3,886.1%-1,270.1%-728.5%-585.8%
Net Margin % -496.8%-184.6%-28.0%-133.0%-60.1%-44.1%-321.7%-81.4%-80.1%-179.6%-981.2%-3,782.4%-1,263.0%-966.5%-560.3%
ROE % -303.6%-52.2%-15.6%-22.2%-32.4%-20.8%-25.4%-22.1%-12.2%-27.6%-26.9%-62.8%-77.2%-177.6%-112.5%
ROCE % -137.1%-36.2%-14.3%-15.1%-24.3%-18.6%-20.6%-21.0%-13.8%-25.4%-26.0%-63.2%-75.7%-129.6%-114.7%

Shareholding Pattern

Insiders
13.51%
Institutions
22.09%
Public Float
25.54%

Top Institutional Holders

#Holder% HeldSharesValue
1 Geode Capital Management, LLC 2.22% 879.39K $250.63K
2 Vanguard Capital Management LLC 2.06% 814.91K $232.25K
3 Blackrock Inc. 1.78% 703.80K $200.58K
4 AdvisorShares Investments, LLC 1.71% 678.48K $193.37K
5 Citadel Advisors Llc 1.10% 437.32K $124.64K
6 Vanguard Fiduciary Trust Co 1.06% 419.41K $119.53K
7 Renaissance Technologies, LLC 0.72% 286.61K $81.68K
8 State Street Corporation 0.51% 200.80K $57.23K
9 Northern Trust Corporation 0.43% 170.27K $48.53K
10 DEARBORN PARTNERS LLC 0.30% 118.80K $33.86K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IGC

Google News ue, 09 Jun 2026

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMzdoczJGNkFyM0lGbE5BNTVORkZCdUg3UEJISUtOQ0poamR4X2JyVjBIVG1DSXZHRW8wRHlGTUplVHNTZzZoVnlGSDJ0eXRfdVBuNm92S1piYXZacGZST1k1RWNDdXhOVnpHbEwyWmtpNTVIR1h1SnVrYmNrODFidVhRZzNHVGdWOFE2cF…

Google News hu, 09 Jul 2026

IGC Pharma puts AI tools on display for Alzheimer’s research in London - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPejVaRmctYnZvbmt5M1hKeWFWQVhock0xTkFPSmZWalhiSFF5bHhQRE94SHRKVjdhYmNtaTQtemlTbkFodHdrbkt4WW9NM2VOdU9SZ2VnNXlOVXMxd3pDNnZNZ1dRVlhfRVBqN3ZFVkpReTBMc1NhYy1SNlVWcHNDT3FScC1EV0QzbjJabk…

Google News Wed, 27 May 2026

IGC - Finviz

<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTFA3UnJCUFdMeHNCRmNwN21PQ0drQUhrTVVfT2FvUTRXeHE5N0ZWQV9FYWRYNWR2WFQ0RUpkMm5xdVNmc3N5?oc=5" target="_blank">IGC</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News Mon, 07 Sep 2026

Price to earnings forward of IGC Pharma, Inc. – AMEX:IGC - tradingview.com

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNTWlCRXJnQW9DS0Z3dzM3cHQzWWM3bjNaVXZ1X3JWaWh6NmhUaHFBME94MnV3UWJDTG5vQ0t6cUFzWDNuZmppNzJPRmpHLVRWOGFDTWUtZjE1cUtJSVBwaFJrZk9ucHdrSzU2bzlCc0otbkR4N0FvS3pVMzhyUWJma0E0Z2hCbjB1S2lSR3…

Google News Sat, 20 Dec 2025

Would You Still Hold IGC Pharma Stock If It Fell Another 30%? - Trefis

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOeXYtUi05QkJDaXdOR1BHVm9lUVpmdWk1bmM3NnZzT09PNFpxM2RFZHFNWDhhaUE2OHJVM2hfbkFaemREOG9XVVJhS0hTaDNWdVRnTUdPSlVHMExQZUluWmdSWFNueHRSTlBvTFpmLXVpYWszQ04zSUJ5ZnBXb2VSZHVVcVZhM2EwZlBzMz…

Google News Wed, 22 Apr 2026

TLRY, CGC, IGC Stocks Light Up On Trump Pot Reclassification Hopes This Week - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQdER4eXdoR3YxRS1DS0NfSW9uMTJpbHBkLXJxNEZhUHFtTWszM2x2bTU5clVyTERXUnBMdTM5WVplNVhOTVhNcGpOeE1iZ00tRDJ6UlJSMEx1b0lVcHhwVjVnMkkwcnB2WlhTQjA1MTN2bEhGaXdvd0RGRTZteDNPNnV6RXhDbkpaSzl3c0…

IGC — Frequently Asked Questions

What is the current share price of IGC Pharma, Inc. (IGC)?

As of 2026-09-19 21:16 PDT, IGC Pharma, Inc. (IGC) trades at $0.29 on NYSE American. Its 52-week range is $0.24 to $0.47.

What is the market capitalisation of IGC?

IGC Pharma, Inc. (IGC) has a market capitalisation of $29.98M on NYSE American.

What is the P/E ratio of IGC?

IGC trades at a trailing price-to-earnings (P/E) ratio of -4.83. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.75.

What is the return on equity (ROE) of IGC?

IGC has a return on equity (ROE) of -83.34%. Its return on capital employed (ROCE) is -114.73%.

Is IGC a good stock to buy?

This page provides a data-driven analysis of IGC Pharma, Inc. (IGC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space